{"doi":"10.1016/j.ymthe.2025.03.004","title":"CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials","abstract":null,"journal":"Molecular Therapy","year":2025,"id":613318,"datarank":0.5606504427425053,"base_score":3.7376696182833684,"endowment":3.7376696182833684,"self_citation_contribution":0.5606504427425053,"citation_network_contribution":0.0,"self_endowment_contribution":0.5606504427425053,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":41,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":90587,"name":"Donald M. O’Rourke","orcid":"0000-0002-8479-7314","position":1,"is_corresponding":false},{"id":263102,"name":"Zev A. Binder","orcid":"0000-0003-1158-231X","position":2,"is_corresponding":false},{"id":1579972,"name":"Sabrina L. Begley","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials","abstract":"Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis and few effective treatment options. Focus has shifted toward using immunotherapies, such as chimeric antigen receptor (CAR) T cells, to selectively target tumor antigens and mediate cytotoxic activity within an otherwise immunosuppressive tumor microenvironment. Between 2015 and 2024, the results of eight completed and two ongoing phase I clinical trials have been published. The majority of studies have treated recurrent GBM patients, although the inter- and intra-patient tumor heterogeneity has been historically challenging to overcome. Molecular targets have included EGFR, HER2, and IL13Rα2 and there has been continued development in improving receptor constructs, identifying novel targets, and adding adjuvant enhancers to increase efficacy. CAR T cells have been safely administered through both peripheral and locoregional routes but with variable clinical and radiographic efficacy. Most trials utilized autologous T cell products to avoid immune rejection yet were unable to consistently show robust engraftment and persistence within patients. Nonetheless, targeted immunotherapies such as CAR T cell therapy remain the next frontier for GBM treatment, and the popularity and complexity of this undertaking is evident in the past, present, and future landscape of clinical trials.","is_dataset_classified":null,"base_score":3.6635616461296463,"endowment":3.6635616461296463,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40057825","pmcid":"PMC12172181","openalex_id":"https://openalex.org/W4408250577","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"R37 CA285434","title":null},{"funder_name":"National Institutes of Health National Cancer Institute","grant_id":"","title":null},{"funder_name":"University of Pennsylvania Perelman School of Medicine","grant_id":"","title":null}],"total_grants":3,"fwci":19.0823,"citation_percentile":0.99553424,"influential_citations":0,"citation_trend":[{"year":2025,"count":13},{"year":2026,"count":25}],"oa_status":"bronze","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.ymthe.2025.03.004","host_type":"journal"},{"url":"https://doi.org/10.1016/j.ymthe.2025.03.004","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1525001625001789?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1525001625001789?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40057825","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12172181/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12172181","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12172181?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["CAR-T cell therapy research","Viral Infectious Diseases and Gene Expression in Insects","Humans","Glioblastoma","Immunotherapy, Adoptive","Receptors, Chimeric Antigen","Clinical Trials as Topic","Brain Neoplasms","T-Lymphocytes","Tumor Microenvironment","Receptors, Antigen, T-Cell","Treatment Outcome","Antigens, Neoplasm"],"mesh_terms":["Receptors, Chimeric Antigen","Antigens, Neoplasm","Brain Neoplasms","Clinical Trials as Topic","Glioblastoma","Humans","Receptors, Antigen, T-Cell","T-Lymphocytes","Immunotherapy, Adoptive","Treatment Outcome","Tumor Microenvironment"],"keywords":["Glioblastoma","Clinical trial","Medicine","Genetic enhancement","Cell therapy","Oncology","Cancer research","Internal medicine","Cell","Biology","Genetics","Gene","EGFR","Clinical Trials","Car T Cells","Il13rα2","Chimeric Antigen Receptor T Cells"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"},{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T07:36:11.931692Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}